🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honoured to co-chair this meeting with Triparna Sen (Sen-Lab), Celine Mascaux Tetsuya Mitsudomi and Aaron Tan. So excited to announce our amazing faculty that includes Charles Swanton and Daniel Tan plus many other leaders in translational lung cancer research. Hope to see you there!

If you’re interested in learning about #lungcancer and #melanoma vaccines, check out this podcast featuring Professor Georgina Long AO (Bluesky @gvlongphdmd) and O'BYRNE Ken Thoracic Oncology Group of Australasia open.spotify.com/episode/0OJbTP… podcasts.apple.com/au/podcast/vac…

Congratulations to the newly elected IASLC board members - so many great candidates this year - can't wait to see what they have in store! Alex A. Adjei Triparna Sen (Sen-Lab) Mary Pasquinelli Isabelle Opitz Hidehito HORINOUCHI Clarissa Baldotto Narjust Florez, MD, FASCO

Alfredo Addeo MD Solange Peters Marius.Ilié Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Xiuning Le MD PhD Andrea R. Filippi Noemi Reguart Patrick Forde Stephanie Saw Tom Newsom-Davis Rami Manochakian MD, FASCO Cancer Education Prof Tom John Curioni_Oncology_MD Mehrpouya Mobin

🆕JUST IN🆙 🌧️Voluntarily Withdrawn 💉Patritumab Deruxtecan (HER3-DXd) 🎯OS did not meet statistical significance 🎙️ U.S. FDA Merck merck.com/news/patrituma… #LCSM OncoAlert LARVOL

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic NSCLC: final, 6-year outcomes from CheckMate 9LA in ESMO Open. Durable OS benefit as compared to platinum-based CT, no new safety signals. esmoopen.com/article/S2059-…

🆕 #ASCO25 🆙 ☑️Developmental Tx, Oral 🔥MONSTAR-SCREEN-3: Ultra-sensitive pan-cancer #MRD assessment using whole-genome sequencing-based personalized ctDNA panel 🎙️ Dr. Tadayoshi Hashimoto 🎯100% baseline sensitivity (41/41) OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

Registration is now open for the 7th International Lung Cancer Summit #ILCS25! Connect with our hosts, Alfredo Addeo MD & Solange Peters, and leading experts to get the latest developments in thoracic oncology 🫁 🗓️ 26 September from 9:30AM CEST ⬇️ Secure your seat early

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Dr. Jamie Chaft with NEOADAURA at #ASCO25. Neoadjuvant osimertinib alone or with chemo vs neoadjuvant chemo in NSCLC. MPR only 2% with chemo, vs 25% with osi, 26% with osi/chemo. pCR 9% osi, 4% osi/chemo. EFS better for pts who MPR - curious how adjuvant osi contributed to EFS.

🔥🚨OncoAlert Hot Off The Press Just published Journal of Clinical Oncology in conjunction with presentation ASCO #ASCO25 ✅Results of #NeoADAURA trial of: #Neoadjuvant #Osimertinib + Chemo Vs #Osimertinib Vs #Chemo in #Resectable #EGFR+ stage II–IIIB non-small-cell #LungCancer. 👇🏻

#ASCO25 After 30 years of failed trials, #tarlatamab changes SoC for our pts with relapsed #SCLC : ✅ mOS: 13.6 vs 8.3 months, HR=0.6, p<0.001 ✅ improved QoL (dyspnea and cough) ✅ 27% vs 62% G3 TRAEs Grateful to all collaborators, Amgen 🧪🔬🧬 science team and above all our pts

Well this has become a very popular Thoracic Oncology Group of Australasia podcast. If you havent listened, worth tuning in to hear Professor Georgina Long AO (Bluesky @gvlongphdmd) and O'BYRNE Ken discussing vaccines in cancer. It’s on all streaming platforms, but here’s the link to Spotify #LCSM #NSCLC #cancervaccines open.spotify.com/episode/0OJbTP…

Global trends in lung cancer reported Lung Cancer Journal. Notable for general increase in lung cancer incidence and mortality in women, esp France (incidence) and Norway (mortality). Increases noted in some countries despite decrease in tobacco use (Japan). lungcancerjournal.info/article/S0169-…

🎉 We’re Turning 5! 🎉 Today marks 5 amazing years since TOGA began its journey! As we celebrate this milestone, we want to acknowledge the incredible role our members have played in shaping our story. Your involvement, ideas, and support have helped us grow, evolve,

Loving this ⁦mayhemtom⁩ track, a lovely collaboration with ⁦Dean Fennell FRCP⁩ on synths. Inspired by the “Pale blue dot speech” from Carl Sagan. Check it out on all streaming platforms details here: mayhemtom.com.au

What’s next in the evolving landscape of EGFR and ALK targeting in NSCLC? 🫁 Prof Tom John from Australia will explore where we are – and what’s ahead for personalized strategies that drive outcomes. ✅ Register now for the ILCS on 26ᵗʰ September and join the conversation ⬇️